The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Acquisition-hungry drug maker Valeant Pharmaceuticals has Allergan in its sights.
Acquisition-hungry drug maker Valeant Pharmaceuticals has Allergan in its sights.
(Ryan Remiorz/THE CANADIAN PRESS)

A Valeant effort: Growing drug maker can’t stop buying

Don’t be discouraged if you have trouble determining Valeant Pharmaceuticals International Inc.’s true value. The drug maker’s acquisition pace makes it almost impossible to peg.

Since Valeant tied up with Biovail Corp. in 2010, the company has embarked on an ambitious acquisition spree, striking 21 deals worth more than $14-billion in a little over three years. Every time shareholders get a chance to catch a breather and assess the future, management goes hunting again. Now the executive team wants to team up with Bill Ackman on a brand new $47-billion deal.